Shapiro AB, Corder AB, Ling V. P-glycoprotein-mediated Hoechst 33342 transport out
of the lipid bilayer. Eur J Biochem 1997;250:115–121.
Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein-mediated drug
transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J
Biochem 1999;259:841–850.
Shepard RL, Cao J, Starling JJ, Dantzig AH. Modulation of P-glycoprotein but not
MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 2003;103:
121–125.
Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, Sugiyama Y. Function of uptake
transporters for taurocholate and estradiol 17b-D-glucuronide in cryopreserved
human hepatocytes. Drug Metab Pharmacokinet 2003;18:33–41.
Shitara Y, Sato H, Sugiyama Y. Evaluation of drug–drug interaction in the hepatobiliary
and renal transport of drugs. Ann Rev Pharmacol Toxicol 2005;45:689–723.
Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and
tissue distribution. Eur J Pharm Sci 2006;27:425–446.
Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–
drug interactions and interindividual differences in transporter and metabolic
enzyme functions. Pharmacol Ther 2006;112:71–105.
Siedlik P, Olson S, Yang B, Stern R. Erythromycin coadministration increases plasma
atorvastatin concentrations. J Clin Pharmacol 1999;39:501–504.
Siegmund W, Ludwig K, Engel G, Zschiesche M, Franke G, Hoffmann A, Terhaag B,
Weitschies W. Variability of intestinal expression of P-glycoprotein in healthy
volunteers as described by absorption of talinolol from four bioequivalent tablets. J
Pharm Sci 2003;92:604–610.
Sigel E. Use of Xenopus oocytes for the functional expression of plasma membrane
proteins. J Membr Biol 1990;117:201–221.
Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS,
Schneck DW. Rosuvastatin pharmacokinetics in heart transplant recipients
administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther
2004;76:167–177.
Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal
allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59:301–321.
Sobrero AF, Handschumacher RE, Bertino JR. Highly selective drug combinations for
human colon cancer cells resistantin vitroto 5-fluoro-2^0 -deoxyuridine. Cancer Res
1985a;45:3161–3163.
Sobrero AF, Moir RD, Bertino JR, Handschumacher RE. Defective facilitated
diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2^0 -
deoxyuridine in the HCT-8 human carcinoma line. Cancer Res 1985b;45:3155–3160.
Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn J-Y, Sadoun A, Pignon B,
Berthou C, Maloisel F, Guyotat D., Casassus P, Ifrah N, Lamy Y, Audhuy B,
Colombat P, Harousseau JL. Combination of Quinine as a potential reversing agent
with mitoxantrone and cytarabine for the treatment of acute leukemias a randomized
multicenter study. Blood 1996;88:1198–1205.
Solary E, Drenou B, Campos L, De Cremoux P, Mugneret F, Moreau P, Lioure B,
Falkenrodt A, Witz B, Bernard M, Hunault-Berger M, Delain M, Fernandes J,
198 DRUG TRANSPORTERS IN DRUG DISPOSITION, DRUG INTERACTIONS